Brief: Nuvation Bio Announces Pivotal Global Phase 3 Sigma Trial (G203) For Safusidenib In Idh1-Mutant Glioma
09/02/2026 15:07
Feb 9 (Reuters) - Nuvation Bio Inc NUVB.N: NUVATION BIO ANNOUNCES PIVOTAL GLOBAL PHASE 3 SIGMA TRIAL (G203) FOR SAFUSIDENIB IN IDH1-MUTANT GLIOMA Source text: ID:nBwYxRcga Further company coverage: NUVB.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nuvation Bio
See all newsBrief: Nuvation Bio To Expand Pivotal Phase 3 Sigma Study Of Safusidenib For Idh1-Mutant Glioma To Six European Countries
Brief: Nuvation Bio To Report Third Quarter 2026 Financial Results And Provide Business Update On November 4, 2026
U.S. RESEARCH ROUNDUP-Everpure, Marvell Technology, Okta
Nuvation Bio Inc. reports results for the quarter ended June 30 - Earnings Summary
Nuvation Bio Q2 revenue beats estimates on IBTROZI growth